Eylea aflibercept ophthalmic solution regulatory update

Regeneron disclosed in its 4Q11 earnings that FDA accepted for review an sBLA for Eylea aflibercept to treat central retinal vein occlusion (CRVO). The PDUFA date is Sept. 23. Regeneron said Bayer's B...